Therefore, the role of RAS and BRAF testing in CRC in many centers in Brazil is to appropriately select patients for anti-eGFR therapy in the first-line setting, since panitumumab or cetuximab is usually available in both public and private systems. This evidence concerns the gene BRAF and colorectal carcinoma.